Mecobalamin Encyclopedia — Scientific Background

What Is Mecobalamin?

Mecobalamin (CAS 13422-55-4), also known as methylcobalamin, MeCbl, or Coα-[α-(5,6-dimethyl-1H-benzimidazol-1-yl)]-Coβ-methylcobamide, is the biologically active, coenzyme form of vitamin B12. It is chemically characterized by the molecular formula C₆₃H₉₁CoN₁₃O₁₄P and a molecular weight of 1344.38 g/mol. Mecobalamin occurs as dark red crystals or crystalline powder that is soluble in water and slightly soluble in methanol, with a melting point greater than 300°C. It is a member of the cobalamin family of compounds and is the predominant form of vitamin B12 found in human plasma and tissues.

The Active B12 Advantage

Mecobalamin is the predominant circulating form of vitamin B12 in human plasma and is directly utilized by the body without requiring enzymatic conversion. Unlike cyanocobalamin, which must be converted to methylcobalamin or adenosylcobalamin in the body, mecobalamin is directly bioavailable at the cellular level. This direct bioavailability makes mecobalamin particularly valuable for individuals with impaired conversion capacity and for applications requiring rapid tissue availability.

Physiological Functions of Mecobalamin

Mecobalamin is critical for numerous physiological functions:

• Red Blood Cell Formation — Mecobalamin is essential for normal red blood cell formation and helps prevent megaloblastic anemia.

• Neurological Function — Mecobalamin supports neurological function and myelin sheath maintenance, contributing to normal nervous system function and cognitive health.

• Homocysteine Regulation — Mecobalamin is a cofactor for methionine synthase, which converts homocysteine to methionine, supporting healthy homocysteine metabolism.

• DNA Synthesis — Mecobalamin is required for DNA synthesis and cellular division.

• Energy Metabolism — Mecobalamin contributes to normal energy-yielding metabolism and helps reduce tiredness and fatigue.

• Immune Function — Mecobalamin supports normal immune system function.

The Stability Challenge

Despite its essential physiological functions, native mecobalamin presents significant formulation and stability challenges. The compound is highly light-sensitive. Due to the strong electron-withdrawing effect of the alkyl group at the β-position of the cobalt ion in mecobalamin's molecular structure, the Co-CH₃ bond energy is weakened, making it highly susceptible to cleavage upon light exposure. Mecobalamin is stable in plasma only when exposed to less than 10 lux of light in amber tubes, and it is stable in plasma at room temperature for 21 hours when exposed to less than 10 lux of light in amber tubes.

These stability challenges have driven the development of advanced delivery systems, including liposomal encapsulation. Mecobalamin-loaded ultra-flexible liposomes achieved a particle size of 124 ± 3 nm with an encapsulation efficiency of approximately 42%, maintaining stability for up to 4 weeks. The liposomal formulation penetrated deeper into the epidermis and dermis of porcine ear skin compared to free drug and demonstrated biocompatibility with no cytotoxic effects on human dermal fibroblasts.

Liposomal Mecobalamin

Liposomal encapsulation of mecobalamin provides a fundamentally different delivery mechanism from conventional forms. The phospholipid bilayer surrounds the mecobalamin molecule, forming a protective shell that enhances stability, bioavailability, and cellular uptake. This delivery system:

• Significantly prolongs drug residence time in vivo (MRT extended to 121 hours)

• Achieves up to 191.89% bioavailability compared to conventional formulations

• Protects mecobalamin from light-induced degradation and Co-CH₃ bond cleavage

• Enhances penetration into the epidermis and dermis with a deformability index close to 1

• Provides sustained release for prolonged enzymatic cofactor activity

Clinical Evidence

Diabetic Peripheral Neuropathy — Randomized Controlled Trial

A 16-week randomized controlled trial enrolled adults with type 2 diabetes, diabetic peripheral neuropathy, and low serum vitamin B12 levels (<200 pg/mL). Patients were randomly assigned to receive either 1,000 μg or 2,000 μg of oral vitamin B12 (methylcobalamin) daily. Both groups experienced significant improvements in neuropathy symptoms. Mean NRS scores decreased from 7.00 ± 2.03 to 5.60 ± 2.19 (p=0.016) in the 1,000 μg group and from 6.18 ± 2.40 to 4.42 ± 2.50 (p=0.007) in the 2,000 μg group. MNSIE scores improved from 5.70 ± 1.66 to 5.22 ± 1.99 (p=0.033) and from 5.40 ± 1.68 to 4.47 ± 2.25 (p=0.022), respectively. No significant difference in neuropathic outcomes was observed between the two dosage groups.

Chemotherapy-Induced Peripheral Neuropathy — Ongoing Clinical Trial

A clinical trial is evaluating the efficacy and safety of mecobalamin in preventing taxane-related peripheral neuropathy. Participants receive oral mecobalamin 0.5 mg three times daily (total 1.5 mg/day), starting on the first day of taxane chemotherapy and continuing until completion of chemotherapy.

Amyotrophic Lateral Sclerosis — Phase 3 Extension Study

A phase 3 extension study is evaluating the long-term safety of ultra-high-dose methylcobalamin (50 mg intramuscular, twice weekly) in patients with advanced amyotrophic lateral sclerosis. The open-label study follows patients receiving 50 mg intramuscular methylcobalamin twice weekly for up to one year.

Safety and Regulatory

Mecobalamin has a well-established safety profile. It is a water-soluble vitamin, and excess amounts are excreted in the urine. No tolerable upper intake level (UL) has been established for vitamin B12 due to its low toxicity.

Regulatory Status:

• United States — Mecobalamin is regulated as a dietary supplement ingredient. It is listed in the FDA Global Substance Registration System with CAS Registry No. 13422-55-4.

• Japan — Mecobalamin is monographed in the Japanese Pharmacopoeia (JP19) with an assay specification of 98.0%–101.0% on anhydrous basis. It is approved as a pharmaceutical ingredient (JAN/INN) and is classified as a third-class OTC drug.

• Global Standards — Mecobalamin is monographed in the Japanese Pharmacopoeia, European Pharmacopoeia, and USP. The product is available with Halal and Kosher certifications.

Precautions: Mecobalamin is generally well tolerated. Individuals with known hypersensitivity to cobalt or cobalamin derivatives should avoid supplementation. Mecobalamin may interact with certain medications, including chloramphenicol, proton pump inhibitors, and metformin. Pregnant or lactating women and children should consult a healthcare professional before use.

Testing protocols must adhere to international standards including USP, European Pharmacopoeia, and FAO/WHO Codex Alimentarius. Formulators should verify local regulatory requirements prior to market entry.

This product is intended for research, nutraceutical, and functional food applications. Not intended to diagnose, treat, cure, or prevent any disease.

99$/KG